These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Spontaneous adverse event notifications by patients subsequent to the marketing of a new formulation of Levothyrox Viard D; Parassol-Girard N; Romani S; Van Obberghen E; Rocher F; Berriri S; Drici MD Fundam Clin Pharmacol; 2019 Aug; 33(4):463-470. PubMed ID: 30575110 [TBL] [Abstract][Full Text] [Related]
18. [Levothyrox : time of reason]. Bertagna X; Bouchard P; Grimaldi A; Wémeau JL; Young J Rev Prat; 2018 Feb; 68(2):123-125. PubMed ID: 30801135 [No Abstract] [Full Text] [Related]
19. Is levothyroxine requirement the same for tablet and soft gel formulations? Di Donna V; Paragliola RM; de Waure C; Papi G; Pontecorvi A; Corsello SM Endocrine; 2018 Feb; 59(2):458-460. PubMed ID: 28466401 [No Abstract] [Full Text] [Related]
20. [Are the two formulas of Levothyrox bioequivalent?]. Coste J; Bertagna X; Zureik M; Nicolas P; Ramez P; Hill C; Schlumberger M Rev Prat; 2019 Oct; 69(8):831-837. PubMed ID: 32237644 [No Abstract] [Full Text] [Related] [Next] [New Search]